Fig. 2: PFS and OS according to depth of response.

PFS for CR (A), PR (B), OS for CR (C), PR (D) in DHL vs DEL vs other. CART chimeric antigen receptor T-cell therapy, DEL double expressor lymphoma, DHL double hit lymphoma, Mon months, No number, OS overall survival, PFS progression free survival.